Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

ARNA 4.19 +0.07 (1.70%)
price chart
Arena Pharmaceutical's Belviq Requires Patience And Understanding (ARNA)
As someone with a relatively oversized long position in Arena Pharmaceuticals (NASDAQ:ARNA) I have been somewhat disappointed in the performance of both the stock and Arena's flagship offering, Belviq. Since the launch of Belviq in the late Spring of ...
Related articles »  
Arena Pharmaceuticals (ARNA) Granted US Patent For Ralinepag
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced yesterday that it been granted composition of matter patent by the US Patent and Trademark Office for its pipeline drug ralinepag for the treatment of vasospastic diseases, including pulmonary ...
Stocks Highlights - Arena Pharmaceuticals, Inc (NASDAQ:ARNA), New York ...  Techsonian (press release)
Related articles »  
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq and VIVUS's (NASDAQ: VVUS ) Qsymia reported a combined 283,000 prescriptions ...
Arena And Vivus Investors Need To Watch Orexigen  Seeking Alpha (registration)
Related articles »  
Arena Pharmaceuticals, Inc. Earnings: Looking for More
Most biotech investor would be happy with 30% quarter-over-quarter prescription growth in a market that didn't grow much. But for Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq, the growth is coming off such a small base that it's hard to get too excited.
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows  Zacks.com
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 ...  MarketWatch
Related articles »  
Arena Pharmaceuticals, Inc., Loews Corporation, and Sysco Corporation ...
As Capitol Hill keeps its eyes closely trained on November elections, Wall Street's attention is elsewhere as earnings season continues this week.
Related articles »  
Why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is Rising?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) surged as much as 6.6%. It was a welcome reprieve for Arena shareholders, who had seen the stock lose 25% of its value this year before today's gains.
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?  Zacks.com
Geron Corp (NASDAQ:GERN) Skyrockets on Unusual Volume - Arena ...  StreetWise Report
Related articles »  
Arena Pharmaceuticals Issued Composition of Matter Patent by United States ...
25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S.
Arena Pharma granted patent for pulmonary hypertension drug  San Diego Source (subscription)
Related articles »  
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare ...
24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -0.72% announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014, ...
Belviq And Smoking Cessation - Clearing The Air
When Arena Pharmaceuticals (NASDAQ:ARNA) announced that a trial for Belviq as a smoking cessation product was being enrolled, I saw opportunity.
Related articles »  
Arena Offers Tease On Belviq And Phentermine (ARNA)
Arena announced that the 12 week study involving 238 patients met the safety endpoints, but the company stopped short of announcing the results of weight loss, opting to save that data for the Obesity Week Conference next week.
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot ...  PipelineReview.com (press release)
Related articles »